+30 years of biopharma industry experience. Sarah was CBO of VectivBio during the IPO on NASDAQ and drove acquisition and integration of Comet Therapeutics as well as a substantial Japan partnering deal with Asahi Kasei. Previously, Sarah was Global Head of Licensing and Head of R&D at Lonza and led the External Science and Partnering team at Sanofi. She held positions of increasing responsibility with Roche for over a decade, where she drove notable deals in oncology and CNS and built and led the M&A assessment and integration team. In her last role at Roche, Sarah was the Lifecycle Leader for Alecensa during FDA and EMA submission. Prior to Roche, she held commercial roles in diagnostics, biotech and pharma, culminating in global launch of Faslodex for AstraZeneca. Sarah is also President of the Swiss Healthcare Licensing Group.